Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8805151 | 0.75 | DRD2 (0.53) | DRD2DRD4DRD3CALM1TAAR1 | |
| SCHEMBL20150693 | 0.74 | CYP3A4 (0.46) | CYP3A4KMT2A | |
| SCHEMBL9618008 | 0.73 | CALM1 (0.49) | KDM4EKMT2ACALM1TAAR1SIGMAR1 | |
| SCHEMBL18214339 | 0.73 | CYP3A4 (0.78) | CYP3A4DRD2DRD4DRD3TAAR1 | |
| SCHEMBL2690240 | 0.71 | SLC6A4 (0.66) | TAAR1MAOB | |
| SCHEMBL9291908 | 0.68 | MAOB (0.56) | CALM1TAAR1SIGMAR1SLC18A2MAOB | |
| SCHEMBL9291906 | 0.68 | MAOB (0.56) | CALM1TAAR1SIGMAR1SLC18A2MAOB | |
| SCHEMBL6790873 | 0.68 | CYP3A4 (0.51) | CYP3A4DRD2DRD4DRD3TAAR1 | |
| SCHEMBL16838790 | 0.68 | MAOB (0.63) | TAAR1SIGMAR1MAOB | |
| SCHEMBL20150779 | 0.67 | CYP3A4 (0.47) | CYP3A4DRD2DRD4DRD3SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134679-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134679-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NQO1, VHL, XIAP | CYP3A4 2215/4885DRD2 4296/4885DRD4 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.